Related Experiment Video
Updated: Mar 6, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells -
Agata Jarząb1, Jarogniew J Łuszczki2, Małgorzata Guz1
1Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Background/Aim:
The aim of this study was to assess the anticancer effect and the type of pharmacologic drug-drug interaction of cisplatin (CDDP) and histone deacetylase inhibitors (HDIs) combined treatment on the rhabdomyosarcoma cell line.
Materials And Methods:
The antiproliferative actions of cisplatin and suberoylanilide hydroxamic acid (SAHA, vorinostat), as well as valproic acid (VPA) alone and in combination, were evaluated using the tetrazolium dye-based MTT cell proliferation assay and isobolographic analysis.
Results:
All tested compounds inhibited proliferation of rhabdomyosarcoma cancer cells in a dose-dependent manner. The combinations of CDDP with SAHA and CDDP with VPA produced additive interaction with type-I isobolographic analysis.
Conclusion:
When adding SAHA or VPA to CDDP therapy, one can expect additive anticancer effects in the rhabdomyosarcoma cell line.
